According to data primarily derived from the SOLOIST-WHF trial (SGLT2 Inhibition With Dapagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction), which was the leading study in terms of hard evidence regarding the benefits of SGLT2 inhibitors in HFpEF with DM [42], a meta-analysis concluded that SGLT2 inhibitors are associated with a greater likelihood of mitigating the risk of cardiovascular disease and hospitalization for HF in patients with HFpEF [43]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.